Teleflex Incorporated · NYSE:TFX
Teleflex — UBS Global Healthcare Conference 2017
13 slides from Teleflex's conference presentation, Jun 14, 2017
Slide 1: Teleflex Incorporated Investor Presentation
Teleflex Incorporated (NYSE: TFX) Investor Presentation
Slide 2: Important Information
Important Information 2 Forward Looking Statements This presentation and our discussion contain forward-looking information and statements, which inherently involve risks and uncertainties that could cause actual results to differ from those projected or implied in the forward–looking statements. Th
Slide 3: Our Company
Our Company 3 Business Overview Revenue by Market1 • NYSE listed – TFX 5% 10% • Global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce procedure costs 85% • Serving healthcare providers worldwide through a combination of our dire
Slide 4: Our Segments: Vascular North America
Our Segments 4 Vascular North America Revenue by Segment1 • Our vascular access products facilitate a variety of critical care therapies, including the administration of intravenous medications and other therapies and the measurement of blood 13% 19% pressure and taking of blood samples through a si
Slide 5: Our Segments: Anesthesia North America
Our Segments 5 Anesthesia North America Revenue by Segment1 Our anesthesia products include airway and pain management products • Our airway management products are designed to help 13% 19% eliminate airway related complications and improve 9% procedural efficiencies for patients in surgical, critic
Slide 6: Our Segments: Surgical North America
Our Segments 6 Surgical North America Revenue by Segment1 • Our surgical products include: • Ligation and closure products, including clips and sutures 13% 19% used in a variety of surgical procedures 9% 10% • Access ports used in minimally invasive surgical 13% procedures, including robotic surgery
Slide 7: Our Segments: EMEA and Asia
Our Segments 7 EMEA Revenue by Segment1 • Our EMEA segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and 13% 19% cardiac care 9% 10% 13% • For the twelve months ended April 2, 2017, our EMEA segment 9% represented $519.6 million, or
Slide 8: Our Segments: OEM
Our Segments 8 OEM Revenue by Segment1 • Our OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers 13% 19% 9% • Provides custom-engineered extrusions, diagnostic and 10% interventional catheters, sheath / dilator sets and kits, sutures, 13% per
Slide 9: Our Strategy
Our Strategy 9 Position Teleflex to succeed in the healthcare environment of the future Increased utilization Increased economic pressure Capitalize on Teleflex’s scope and size Take advantage of unique Teleflex opportunities Footprint consolidation Distributor to direct conversions
Slide 10: Key Investment Highlights
Key Investment Highlights 10 Diversified, global medical technology company Well-positioned to take advantage of favorable industry dynamics Leading market positions with established global brands Diversified customer and supplier base Strong cash flow generation and proven history of deleveraging a
Slide 11: Thank You
THANK YOU Veleflex:
Slide 12: Appendix
APPENDIX Veleflex:
Slide 13: April 2, 2017 LTM Revenue Data
April 2, 2017 LTM Revenue Data 13 Dollars in Thousands 2016 Revenue: $ 1,868,027 Less - Q1'16 Revenue: $ 424,893 Add - Q1'17 Revenue: $ 487,881 April 2, 2017 LTM Revenue: $ 1,931,015 2016 Revenue Less: Q1'16 Revenue Add: Q1'17 Revenue LTM April 2, 2017 Revenue LTM April 2, 2017 Revenue - % Vascular